Search Results - "Ipilimumab/therapeutic use"

Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis

Authors: Peters, Solange Paz-Ares, Luis G. Reck, Martin et al.

Contributors: Peters, Solange Paz-Ares, Luis G. Reck, Martin et al.

Source: Digital.CSIC. Repositorio Institucional del CSIC
Consejo Superior de Investigaciones Científicas (CSIC)
Journal of thoracic oncology, vol. 20, no. 1, pp. 94-108

Subject Terms: PD-L1, Nivolumab, Non–small cell lung cancer, Humans, Nivolumab/pharmacology, Nivolumab/therapeutic use, Nivolumab/administration & dosage, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/pathology, Carcinoma, Non-Small-Cell Lung/mortality, Lung Neoplasms/drug therapy, Lung Neoplasms/pathology, Lung Neoplasms/mortality, Lung Neoplasms/metabolism, Ipilimumab/pharmacology, Ipilimumab/therapeutic use, Ipilimumab/administration & dosage, Male, Female, Middle Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, B7-H1 Antigen/metabolism, Aged, Adult, Survival Rate, Aged, 80 and over, Follow-Up Studies, Immunotherapy, Ipilimumab

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39369790
http://hdl.handle.net/10261/390933
https://api.elsevier.com/content/abstract/scopus_id/85208360083
https://serval.unil.ch/resource/serval:BIB_89D370D6F09D.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_89D370D6F09D
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_89D370D6F09D7

Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma:Comparison of 3-year data from PRADO and OpACIN-neo

Authors: Reijers, Irene L M Menzies, Alexander M Lopez-Yurda, Marta et al.

Source: Reijers, I L M, Menzies, A M, Lopez-Yurda, M, Versluis, J M, Rozeman, E A, Saw, R P M, van Houdt, W J, Kapiteijn, E, van der Veldt, A A M, Suijkerbuijk, K P M, Eriksson, H, Hospers, G A P, Klop, W M C, Torres Acosta, A, Grijpink-Ongering, L, Gonzalez, M, van der Wal, A, Al-Mamgani, A, Spillane, A J, Scolyer, R A, van de Wiel, B A, van Akkooi, A C J, Long, G V & Blank, C U 2025, 'Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma ....

Subject Terms: Humans, Melanoma/mortality, Neoadjuvant Therapy/mortality, Male, Female, Middle Aged, Neoplasm Staging, Ipilimumab/therapeutic use, Aged, Chemotherapy, Adjuvant, Skin Neoplasms/mortality, Lymph Node Excision, Immune Checkpoint Inhibitors/therapeutic use, Adult, Immunotherapy/methods, Nivolumab/therapeutic use, Precision Medicine/methods, Antineoplastic Combined Chemotherapy Protocols/therapeutic use

File Description: application/pdf

Relation: info:eu-repo/semantics/altIdentifier/pmid/39602990; info:eu-repo/semantics/altIdentifier/hdl/https://hdl.handle.net/11370/a7d83797-0e77-4e1c-9d50-d1c472e1262c; info:eu-repo/semantics/altIdentifier/pissn/0959-8049; info:eu-repo/semantics/altIdentifier/eissn/1879-0852

Availability: https://hdl.handle.net/11370/a7d83797-0e77-4e1c-9d50-d1c472e1262c
https://research.rug.nl/en/publications/a7d83797-0e77-4e1c-9d50-d1c472e1262c
https://doi.org/10.1016/j.ejca.2024.115141
https://pure.rug.nl/ws/files/1277673260/1-s2.0-S0959804924017489-main.pdf
https://www.scopus.com/pages/publications/85210014804

Quality of life under treatment with the immune checkpoint inhibitors ipilimumab and nivolumab in melanoma patients. Real-world data from a prospective observational study at the Skin Cancer Center Kiel

Authors: Grote, Carolin Bohne, Ann-Sophie Blome, Christine et al.

Source: J Cancer Res Clin Oncol

Subject Terms: Male, Adult, Aged, 80 and over, Skin Neoplasms, Research, Surveys and Questionnaires [MeSH], Aged, 80 and over [MeSH], Melanoma, Aged [MeSH], Skin Neoplasms/drug therapy [MeSH], Nivolumab/adverse effects [MeSH], Ipilimumab/administration, Male [MeSH], Immune Checkpoint Inhibitors/adverse effects [MeSH], Melanoma/pathology [MeSH], Quality of Life [MeSH], Skin Neoplasms/immunology [MeSH], Melanoma/drug therapy [MeSH], HrQoL, Female [MeSH], Adult [MeSH], Humans [MeSH], Prospective Studies [MeSH], Ipilimumab/adverse effects [MeSH], Middle Aged [MeSH], Skin Neoplasms/pathology [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], ICI, Immune Checkpoint Inhibitors/therapeutic use [MeSH], Distress thermometer, Antineoplastic Combined Chemotherapy Protocols/adverse effects [MeSH], Ipilimumab/therapeutic use [MeSH], IBDQ-D, SF-36, Nivolumab/administration, Nivolumab/therapeutic use [MeSH], Middle Aged, Ipilimumab, Nivolumab, Surveys and Questionnaires, Antineoplastic Combined Chemotherapy Protocols, Quality of Life, Humans, Female, Prospective Studies, Immune Checkpoint Inhibitors, Aged

Access URL: https://pubmed.ncbi.nlm.nih.gov/39387946
https://repository.publisso.de/resource/frl:6497979

Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1

Authors: Martin Reck Tudor-Eliade Ciuleanu Jong-Seok Lee et al.

Contributors: Martin Reck Tudor-Eliade Ciuleanu Jong-Seok Lee et al.

Source: Digital.CSIC. Repositorio Institucional del CSIC
Consejo Superior de Investigaciones Científicas (CSIC)
Journal of thoracic oncology, vol. 18, no. 8, pp. 1055-1069

Subject Terms: Adult, Lung Neoplasms, Brain Neoplasms, Humans, Nivolumab/pharmacology, Nivolumab/therapeutic use, Ipilimumab/pharmacology, Ipilimumab/therapeutic use, B7-H1 Antigen/metabolism, Lung Neoplasms/pathology, Neoplasm Recurrence, Local/drug therapy, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/chemically induced, Brain Neoplasms/drug therapy, Brain Neoplasms/secondary, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Brain metastases, Intracranial outcomes, Ipilimumab, NSCLC, Nivolumab, B7-H1 Antigen, 3. Good health, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/37146754
http://hdl.handle.net/10261/353291
https://serval.unil.ch/resource/serval:BIB_9890E6F11421.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_9890E6F11421
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_9890E6F114218

Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands

Authors: Zeijl, M.C.T. van Breeschoten, J. van Wreede, L.C. de et al.

Contributors: Zeijl, M.C.T. van Breeschoten, J. van Wreede, L.C. de et al.

Source: van Zeijl, M C T, van Breeschoten, J, de Wreede, L C, Wouters, M W J M, Hilarius, D L, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Suijkerbuijk, K P M, Haanen, J B A G & van den Eertwegh, A J M 2023, 'Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands', Journal of Immunotherapy, vol. 46, no. 5, pp. 197-204. https://doi.org/10.1097/CJI.0000000000000468
Journal of Immunotherapy (1997), 46, 5, pp. 197-204

Subject Terms: Cancer Research, Immunology, Radboud University Medical Center, Brain Neoplasms/drug therapy, POOLED ANALYSIS, Nivolumab/therapeutic use, SDG 3 - Good Health and Well-being, Melanoma/pathology, Antineoplastic Combined Chemotherapy Protocols, Journal Article, Immunology and Allergy, METASTATIC MELANOMA, Humans, Melanoma, Netherlands, Pharmacology, Ipilimumab plus nivolumab, Brain Neoplasms, Antineoplastic Combined Chemotherapy Protocols/adverse effects, real world, Clinical Trial, Ipilimumab, 3. Good health, population-based, Nivolumab, SURVIVAL, immunotherapy, Radboudumc 18: Healthcare improvement science Medical Oncology, Ipilimumab/therapeutic use

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/37103470
https://cris.maastrichtuniversity.nl/en/publications/0bab63c2-7c57-472e-b6fd-b12fcc4f0a81
https://doi.org/10.1097/CJI.0000000000000468
https://research.vumc.nl/en/publications/7ee24807-e950-4c44-aff8-949e7f1578bd
https://dspace.library.uu.nl/handle/1874/449093
https://hdl.handle.net/1887/3666123
https://repository.ubn.ru.nl//bitstream/handle/2066/292757/292757.pdf
https://hdl.handle.net/2066/292757

A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors

Authors: Vounckx, Manon Tijtgat, Jens Stevens, Latoya et al.

Contributors: Vounckx, Manon Tijtgat, Jens Stevens, Latoya et al.

Source: Cancer Immunol Immunother

Subject Terms: Thrombomodulin/therapeutic use, Male, Adult, 0301 basic medicine, Thrombomodulin, Antibodies, Monoclonal, Humanized, Radiosurgery, Antigens, CD1, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoplasms/therapy, Humans, Myeloid Cells, Radiosurgery/methods, Aged, Glycoproteins, Aged, 80 and over, Research, Dendritic Cells, Middle Aged, Ipilimumab, Combined Modality Therapy, 3. Good health, Antibodies, Monoclonal, Humanized/therapeutic use, Dendritic Cells/immunology, myeloid cells, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, aged, 80 and over, Ipilimumab/therapeutic use

Access URL: https://pubmed.ncbi.nlm.nih.gov/38954010
https://biblio.vub.ac.be/vubir/a-randomized-phase-ii-clinical-trial-of-stereotactic-body-radiation-therapy-sbrt-and-systemic-pembrolizumab-with-or-without-intratumoral-avelumabipilimumab-plus-cd1c-bdca1cd141-bdca3-myeloid-dendritic-cells-in-solid-tumors(2d7ca664-0776-4429-bb1b-833025e4bf86).html

Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study: A nationwide cohort study

Authors: Not, O.J. van Meza, M.M. de Eertwegh, A.J.M. van den et al.

Contributors: Not, O.J. van Meza, M.M. de Eertwegh, A.J.M. van den et al.

Source: van Not, O J, de Meza, M M, van den Eertwegh, A J M, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, van Breeschoten, J, de Groot, J-W B, Hospers, G A P, Ismail, R K, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A M, van der Veldt, A A M, Vreugdenhil, G, Bonenkamp, H J, Boers-Sonderen, M J, Blokx, W A M, Wouters, M W J M & Suijkerbuijk, K P M 2022, 'Response to immune checkpoint inhibitors in acral melanoma : A nationwide cohort study', European Journal of Cancer, vol. 167, pp. 70-80. https://doi.org/10.1016/j.ejca.2022.02.026
European Journal of Cancer, 167, pp. 70-80

Subject Terms: Radboudumc 18: Healthcare improvement science RIHS: Radboud Institute for Health Sciences, 0301 basic medicine, Cancer Research, Skin Neoplasms, Survival, Melanoma/mortality, THERAPY, SUBTYPES, Cohort Studies, Immune checkpoint inhibitors, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Melanoma, Cutaneous Malignant, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Skin Neoplasms/drug therapy, Journal Article, Humans, Prospective Studies, Immune Checkpoint Inhibitors, Melanoma, OUTCOMES, IPILIMUMAB, Response, KIT, Radboudumc 14: Tumours of the digestive tract RIHS: Radboud Institute for Health Sciences, EFFICACY, Nivolumab/adverse effects, Immune Checkpoint Inhibitors/therapeutic use, Ipilimumab, 3. Good health, MUCOSAL, Nivolumab, Oncology, ARM, Immunotherapy, Ipilimumab/therapeutic use

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/35395553
https://pure.eur.nl/en/publications/1281252e-ffc9-4c63-a584-5f4f694e5c5d
https://doi.org/10.1016/j.ejca.2022.02.026
https://research.rug.nl/en/publications/4eaf37d0-e9eb-444d-8275-f8aa051f3a33
https://hdl.handle.net/11370/4eaf37d0-e9eb-444d-8275-f8aa051f3a33
https://doi.org/10.1016/j.ejca.2022.02.026
https://cris.maastrichtuniversity.nl/en/publications/5c12b11e-cf71-4548-bdb5-f7e35804eab7
https://doi.org/10.1016/j.ejca.2022.02.026
https://research.vumc.nl/en/publications/9ea06a14-8ccd-4a3b-b117-2eb77a7569be
https://dspace.library.uu.nl/handle/1874/446113
https://hdl.handle.net/1887/3563996
https://pure.amsterdamumc.nl/en/publications/f1f99c61-5388-40ac-9168-81365e273462
https://doi.org/10.1016/j.ejca.2022.02.026
https://repository.ubn.ru.nl/handle/2066/250273
https://repository.ubn.ru.nl//bitstream/handle/2066/250273/250273.pdf

First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743

Authors: Scherpereel, A. Antonia, S. Bautista, Y. et al.

Contributors: Scherpereel, A. Antonia, S. Bautista, Y. et al.

Source: Lung cancer, vol. 167, pp. 8-16

Subject Terms: Quality of life, Mesothelioma, Malignant, Lung Neoplasms, Lung Cancer Symptom Scale, Mesothelioma, Malignant, EQ-5D, Immuno-oncology, Ipilimumab, 3. Good health, Immune checkpoint inhibitors, 03 medical and health sciences, Nivolumab, 0302 clinical medicine, Programmed cell death (PD)-1 inhibitor, Antineoplastic Combined Chemotherapy Protocols, Quality of Life, Symptom burden, Humans, Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4), Overall survival, Immunotherapy, Patient Reported Outcome Measures, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Ipilimumab/therapeutic use, Lung Neoplasms/diagnosis, Lung Neoplasms/drug therapy, Lung Neoplasms/etiology, Mesothelioma/drug therapy, Nivolumab/adverse effects

File Description: application/pdf; Print-Electronic

Access URL: https://pubmed.ncbi.nlm.nih.gov/35367910
https://hdl.handle.net/1887/3565034
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_A48722CEDE6A0
https://serval.unil.ch/notice/serval:BIB_A48722CEDE6A
https://serval.unil.ch/resource/serval:BIB_A48722CEDE6A.P001/REF.pdf

CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer

Authors: De Ruysscher, D. Ramalingam, S. Urbanic, J. et al.

Source: Clinical lung cancer, vol. 23, no. 3, pp. e264-e268

Subject Terms: PD-L1, Lung Neoplasms, Cytotoxic T-lymphocyte antigen-4, Progression-free survival, Antibodies, Monoclonal, Immune checkpoint inhibitor, Chemoradiotherapy, OPEN-LABEL, Ipilimumab, 3. Good health, 03 medical and health sciences, Nivolumab, 0302 clinical medicine, Chemoradiation, Carcinoma, Non-Small-Cell Lung, PD-1, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carcinoma, Non-Small-Cell Lung/drug therapy, Humans, Ipilimumab/therapeutic use, Lung Neoplasms/pathology, Nivolumab/therapeutic use, PD-1/PD-L1

File Description: application/pdf

Access URL: http://www.clinical-lung-cancer.com/article/S1525730421001868/pdf
https://pubmed.ncbi.nlm.nih.gov/34489161
https://cris.maastrichtuniversity.nl/en/publications/ead2e25c-fb64-4165-a3b2-0343afe3ef0d
https://doi.org/10.1016/j.cllc.2021.07.005
https://www.sciencedirect.com/science/article/pii/S1525730421001868
https://serval.unil.ch/resource/serval:BIB_800C38154E47.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_800C38154E473
https://serval.unil.ch/notice/serval:BIB_800C38154E47

Long-Term Survival in Patients With Advanced Melanoma

Authors: van Not, Olivier J van den Eertwegh, Alfons J M Jalving, Hilde et al.

Source: van Not, O J, van den Eertwegh, A J M, Jalving, H, Bloem, M, Haanen, J B, van Rijn, R S, Aarts, M J B, van den Berkmortel, F W P J, Blank, C U, Boers-Sonderen, M J, de Groot J W B, J W, Hospers, G A P, Kapiteijn, E, Leeneman, B, D, P, Stevense-den Boer, M, van der Veldt, A A M, Vreugdenhil G, G, Wouters, M W J M, Blokx, W A M & Suijkerbuijk, K P M 2024, 'Long-Term Survival in Patients With Advanced Melanoma', Jama network open, vol. 7, no. 8, e2426641. https://doi.org/10.1001/jamanetworkopen.2024.26641

Subject Terms: Humans, Melanoma/drug therapy, Male, Female, Middle Aged, Aged, Immune Checkpoint Inhibitors/therapeutic use, Netherlands/epidemiology, Ipilimumab/therapeutic use, Nivolumab/therapeutic use, Skin Neoplasms/drug therapy, Cohort Studies, Registries, Progression-Free Survival, Prospective Studies

File Description: application/pdf

Relation: info:eu-repo/semantics/altIdentifier/pmid/39141388; info:eu-repo/semantics/altIdentifier/hdl/https://hdl.handle.net/11370/afb0e25d-a261-46b1-a9dc-a6bda8727d97; info:eu-repo/semantics/altIdentifier/pissn/2574-3805

Availability: https://hdl.handle.net/11370/afb0e25d-a261-46b1-a9dc-a6bda8727d97
https://research.rug.nl/en/publications/afb0e25d-a261-46b1-a9dc-a6bda8727d97
https://doi.org/10.1001/jamanetworkopen.2024.26641
https://pure.rug.nl/ws/files/1089044191/van_not_2024_oi_240826_1723563160.15669.pdf
https://www.scopus.com/pages/publications/85201247625

PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma

Authors: Ellebaek, Eva Khan, Shawez Bastholt, Lars et al.

Source: Ellebaek, E, Khan, S, Bastholt, L, Schmidt, H, Haslund, C A, Donia, M & Svane, I M 2024, 'PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma', European Journal of Cancer, vol. 198, 113476. https://doi.org/10.1016/j.ejca.2023.113476

Subject Terms: Anti-CTLA-4, Anti-PD-1, Immunotherapy, Metastatic melanoma, PD-L1 status, Melanoma/pathology, B7-H1 Antigen, Humans, Ipilimumab/therapeutic use, Combined Modality Therapy, Nivolumab/therapeutic use

File Description: application/pdf

Availability: https://portal.findresearcher.sdu.dk/da/publications/943acb35-2610-46a6-be1c-a947c2a509bb
https://doi.org/10.1016/j.ejca.2023.113476
https://findresearcher.sdu.dk/ws/files/252954354/1-s2.0-S0959804923007785-main.pdf

Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial

Authors: Ten Ham, Renske M T Rohaan, Maartje W Jedema, Inge et al.

Contributors: Ten Ham, Renske M T Rohaan, Maartje W Jedema, Inge et al.

Subject Terms: Cost-Benefit Analysis, Humans, Ipilimumab/therapeutic use, Lymphocytes, Tumor-Infiltrating/pathology, Melanoma/drug therapy, Skin Neoplasms/drug therapy, Molecular Medicine, Oncology, Cancer Research, Immunology and Allergy, Pharmacology, Immunology, Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III, Journal Article

File Description: application/pdf

Relation: https://dspace.library.uu.nl/handle/1874/453576

Availability: https://dspace.library.uu.nl/handle/1874/453576

The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab

Authors: Mallardo, Domenico Woodford, Rachel Menzies, Alexander M et al.

Contributors: Mallardo, Domenico Woodford, Rachel Menzies, Alexander M et al.

Source: J Transl Med
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-11 (2023)
Journal of translational medicine, vol. 21, no. 1, pp. 753

Subject Terms: Nivolumab + relatlimab, LDH, Research, Diabetes, Medizin, 10177 Dermatology Clinic, 610 Medicine & health, Genetics and Molecular Biology, General Medicine, Ipilimumab, 3. Good health, Nivolumab, Glucose, Diabetes Mellitus, Type 2, 1300 General Biochemistry, Genetics and Molecular Biology, General Biochemistry, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humans, Melanoma, Nivolumab/therapeutic use, Diabetes Mellitus, Type 2/complications, Diabetes Mellitus, Type 2/drug therapy, Melanoma/complications, Melanoma/drug therapy, Melanoma/pathology, Ipilimumab/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects

File Description: application/pdf; ZORA_s12967_023_04607_4.pdf - application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/37880788
https://doaj.org/article/f9c9d70fb3694e94a830225a5081faab
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_79C70FD3661F1
https://serval.unil.ch/notice/serval:BIB_79C70FD3661F
https://serval.unil.ch/resource/serval:BIB_79C70FD3661F.P001/REF.pdf
https://www.zora.uzh.ch/id/eprint/252445/
https://doi.org/10.5167/uzh-252445

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)

Authors: Torsten Pietsch Jennifer Landsberg Glen Kristiansen et al.

Source: Cancer Immunol Immunother

Subject Terms: Research Report, Adult, Male, 0301 basic medicine, 03 medical and health sciences, Antineoplastic Agents, Immunological, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic [MeSH], CTLA-4, Aged, 80 and over [MeSH], Melanoma, Aged [MeSH], Male [MeSH], Melanoma/pathology [MeSH], DNA methylation, Melanoma/drug therapy [MeSH], Female [MeSH], Follow-Up Studies [MeSH], Adult [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Melanoma/mortality [MeSH], Predictive biomarker, Ipilimumab/therapeutic use [MeSH], Survival Rate [MeSH], CTLA-4 Antigen/genetics [MeSH], DNA Methylation [MeSH], Antineoplastic Agents, Immunological/therapeutic use [MeSH], Biomarkers, Tumor/genetics [MeSH], Immunotherapy, Prognosis [MeSH], Promoter Regions, Genetic [MeSH], Humans, CTLA-4 Antigen, Promoter Regions, Genetic, 10. No inequality, Aged, Retrospective Studies, Aged, 80 and over, 0303 health sciences, DNA Methylation, Middle Aged, Prognosis, Ipilimumab, ddc, 3. Good health, Gene Expression Regulation, Neoplastic, Survival Rate, Female, Follow-Up Studies

File Description: application/pdf

Access URL: https://link.springer.com/content/pdf/10.1007/s00262-020-02777-4.pdf
https://pubmed.ncbi.nlm.nih.gov/33196890
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139923
https://www.scilit.net/article/a6bc7ad018f132d9f73a17b642cf4466?action=show-references
https://link.springer.com/content/pdf/10.1007/s00262-020-02777-4.pdf
https://www.ncbi.nlm.nih.gov/pubmed/33196890
https://pubmed.ncbi.nlm.nih.gov/33196890/
https://link.springer.com/article/10.1007/s00262-020-02777-4
https://repository.publisso.de/resource/frl:6470084
https://mediatum.ub.tum.de/doc/1624233/document.pdf

Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study

Authors: Rossi, Ernesto Boldrini, Luca Maratta, Maria Grazia et al.

Source: Hum Vaccin Immunother
Human Vaccines & Immunotherapeutics, Vol 19, Iss 1 (2023)
Human vaccines & immunotherapeutics, vol. 19, no. 1, pp. 2172926

Subject Terms: renal cell carcinoma, RM1-950, anti-ctla4, predictive factor, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, features, Humans, ipilimumab, Carcinoma, Renal Cell, Retrospective Studies, nivolumab, Radiomics, anti-CTLA4, Carcinoma, Renal Cell/diagnostic imaging, Carcinoma, Renal Cell/therapy, Antineoplastic Agents, Immunological/therapeutic use, Immunotherapy/methods, Kidney Neoplasms/diagnostic imaging, Kidney Neoplasms/therapy, Ipilimumab/therapeutic use, anti-PD-1, immunotherapy, pembrolizumab, Immunotherapy - Cancer, anti-pd-1, RC581-607, Ipilimumab, Kidney Neoplasms, 3. Good health, radiomics, Therapeutics. Pharmacology, Immunotherapy, Immunologic diseases. Allergy

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/36723981
https://doaj.org/article/a30090309951414494635a8b4eefd632
https://serval.unil.ch/notice/serval:BIB_BFEA01D27F95
https://serval.unil.ch/resource/serval:BIB_BFEA01D27F95.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_BFEA01D27F957
https://hdl.handle.net/10807/232385
https://doi.org/10.1080/21645515.2023.2172926

Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.

Authors: Paz-Ares, L.G. Ciuleanu, T.E. Pluzanski, A. et al.

Subject Terms: Humans, Nivolumab/pharmacology, Nivolumab/therapeutic use, Ipilimumab/pharmacology, Ipilimumab/therapeutic use, Lung Neoplasms/pathology, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carcinoma, Non-Small-Cell Lung/drug therapy, Non-Small-Cell Lung/chemically induced, Immune-mediated adverse events, Ipilimumab, NSCLC, Nivolumab, Safety

Relation: Journal of Thoracic Oncology; https://iris.unil.ch/handle/iris/46681; serval:BIB_0FB9CAD0B375

Availability: https://iris.unil.ch/handle/iris/46681
https://doi.org/10.1016/j.jtho.2022.08.014

The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.

Authors: Martins, F. Schiappacasse, L. Levivier, M. et al.

Subject Terms: Adult, Aged, 80 and over, Antineoplastic Agents, Immunological/therapeutic use, Brain Neoplasms/immunology, Brain Neoplasms/metabolism, Brain Neoplasms/pathology, Brain Neoplasms/therapy, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Immunotherapy/mortality, Ipilimumab/therapeutic use, Male, Melanoma/immunology, Melanoma/metabolism, Melanoma/pathology, Melanoma/therapy, Middle Aged, Molecular Targeted Therapy/mortality, Prognosis, Protein Kinase Inhibitors/therapeutic use, Radiosurgery/mortality, Retrospective Studies, Survival Rate, BRAF, CTLA-4, CyberKnife

Relation: Journal of Neuro-Oncology; https://iris.unil.ch/handle/iris/34983; serval:BIB_18BD1C202E95; 000504965000019

Availability: https://iris.unil.ch/handle/iris/34983
https://doi.org/10.1007/s11060-019-03363-0

Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial.

Authors: Tas, L. Weitemeyer, M.B. Rohaan, M.W. et al.

Subject Terms: Humans, Melanoma/therapy, Melanoma/surgery, Melanoma/secondary, Lymphocytes, Tumor-Infiltrating/transplantation, Female, Male, Middle Aged, Skin Neoplasms/therapy, Skin Neoplasms/surgery, Skin Neoplasms/pathology, Ipilimumab/therapeutic use, Aged, Adult, Treatment Outcome, Antineoplastic Agents, Immunological/therapeutic use, Postoperative Complications/epidemiology, Lymphatic Metastasis

Relation: British Journal of Surgery; https://iris.unil.ch/handle/iris/263402; serval:BIB_FE993A41BA2B; 001502825800001

Availability: https://iris.unil.ch/handle/iris/263402
https://doi.org/10.1093/bjs/znaf090

Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.

Authors: de Joode, K. Mora, A.R. van Schaik, RHN et al.

Subject Terms: Humans, Ipilimumab/adverse effects, Ipilimumab/therapeutic use, CTLA-4 Antigen/genetics, Melanoma/drug therapy, Melanoma/genetics, Melanoma/mortality, Polymorphism, Single Nucleotide, Male, Female, Middle Aged, Aged, Neoplasm Staging, Genotype, Adult, 80 and over, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Treatment Outcome

Relation: Journal of Immunotherapy; https://iris.unil.ch/handle/iris/202646; serval:BIB_B6930E6F147C; 001277944000001

Availability: https://iris.unil.ch/handle/iris/202646
https://doi.org/10.1097/CJI.0000000000000506

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.

Authors: Pires da Silva, I. Zakria, D. Ahmed, T. et al.

Subject Terms: Brain Neoplasms/drug therapy, Female, Humans, Ipilimumab/therapeutic use, Melanoma/drug therapy, Melanoma/genetics, Melanoma/pathology, Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors, Mutation, Neoplasms, Second Primary/drug therapy, Protein Kinase Inhibitors/adverse effects, Protein Kinase Inhibitors/therapeutic use, Proto-Oncogene Proteins B-raf/antagonists & inhibitors, Proto-Oncogene Proteins B-raf/genetics, Skin Neoplasms/drug therapy, Skin Neoplasms/genetics, Skin Neoplasms/pathology, immunotherapy, melanoma

File Description: application/pdf

Relation: Journal for ImmunoTherapy of Cancer; https://iris.unil.ch/handle/iris/192455; serval:BIB_D204CE09BBCB; 000822763900003

Availability: https://iris.unil.ch/handle/iris/192455
https://doi.org/10.1136/jitc-2022-004610